Objectives: Cerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies. Sulfonylurea receptor-1-transient receptor potential cation channel M4 is upregulated only after brain injury, causing edema in animal studies. We hypothesized that sulfonylurea receptor-1 is measurable in human cerebrospinal fluid after severe traumatic brain injury and is an informative biomarker of edema and outcome. Design: A total of 119 cerebrospinal fluid samples were collected from 28 severe traumatic brain injury patients. Samples were retrieved at 12, 24, 48, 72 hours and before external ventricular drain removal. Fifteen control samples were obtained from patients with normal pressure hydrocephalus. Sulfonylurea receptor-1 was quantified by enzyme-linked immunosorbent assay. Outcomes included CT edema, intracranial pressure measurements, therapies targeting edema, and 3-month Glasgow Outcome Scale score. Main Results: Sulfonylurea receptor-1 was present in all severe traumatic brain injury patients (mean = 3.54 ± 3.39 ng/mL, peak = 7.13 ± 6.09 ng/mL) but undetectable in all controls (p < 0.001). Mean and peak sulfonylurea receptor-1 was higher in patients with CT edema (4.96 ± 1.13 ng/mL vs 2.10 ± 0.34 ng/mL; p = 0.023). There was a temporal delay between peak sulfonylurea receptor-1 and peak intracranial pressure in 91.7% of patients with intracranial hypertension. There was no association between mean/peak sulfonylurea receptor-1 and mean/peak intracranial pressure, proportion of intracranial pressure greater than 20 mm Hg, use of edemadirected therapies, decompressive craniotomy, or 3-month Glasgow Outcome Scale. However, decreasing sulfonylurea receptor-1 trajectories between 48 and 72 hours were significantly associated with improved cerebral edema and clinical outcome. Area under the multivariate model receiver operating characteristic curve was 0.881. Conclusions: This is the first report quantifying human cerebrospinal fluid sulfonylurea receptor-1. Sulfonylurea receptor-1 was detected in severe traumatic brain injury, absent in controls, correlated with -5). It is a significant cause of in-hospital death occurring in more than 60% of TBI patients with mass lesions and even occurs in 15% of those with normal initial CT scans (6). Edema can be focal or diffuse, result from multiple etiologies/mechanisms, and can occur remote from the primary injury site (7-11). Although CE develops in the initial 24 hours and peaks at 3-5 days, upstream mechanisms that initiate its development may begin sooner and are potential therapeutic targets.
C erebral edema (CE) is strongly associated with death and unfavorable outcome in traumatic brain injury (TBI) (1) (2) (3) (4) (5) . It is a significant cause of in-hospital death occurring in more than 60% of TBI patients with mass lesions and even occurs in 15% of those with normal initial CT scans (6) . Edema can be focal or diffuse, result from multiple etiologies/mechanisms, and can occur remote from the primary injury site (7) (8) (9) (10) (11) . Although CE develops in the initial 24 hours and peaks at 3-5 days, upstream mechanisms that initiate its development may begin sooner and are potential therapeutic targets.
Critical care management focuses on evaluating and treating CE. Nevertheless, assessment of CE remains limited to suboptimal neurological examinations in intubated/sedated patients, intracranial pressure (ICP) monitors, and imaging. ICP measurements in isolation may represent an insufficient reflection of edema and should be aided by complementary information (12) . Current therapies to reduce CE remain reactionary, nonspecific, and morbid. Early biomarkers identifying targets in the development/treatment of CE represent a critical unmet need.
Many cellular/molecular pathways contribute to posttraumatic CE (10, . TBI is heterogeneous, and edema may result from multiple pathways. In 1905, Reichardt coined the term "brain edema" to differentiate underlying cellular processes from "brain swelling" due to vascular engorgement (11) . Research advances have since implicated multiple molecular pathways involved in TBI-related CE pathogenesis like aquaporin-4, matrix-metalloproteinases, Na+-K(+)-2Cl(-) cotransporter, and sulfonylurea receptor (Sur1)-transient-receptor-potential cation channel member-4 (Trpm4) (10, 17, 19, 22, 25-28, 31, 33-37) . These mechanisms affect blood-brain barrier integrity, cellular volume regulation, oncotic gradients, and inflammatory responses culminating in different forms of CE-described as contusional versus diffuse or categorized as vasogenic, cytotoxic, or osmotic (11) . Characterizing these contributions could facilitate individually tailored, mechanistically precise approaches to treatment/prevention. This biomarker-guided theranostic approach to edema prevention could minimize the risks of reactionary approaches to raised ICP.
Seminal research identified a pathway involving Sur1 in CE development (29) (30) (31) . Sur1 is a transmembrane-receptor that obligatorily associates with a nonselective monovalent cation channel (Trpm4) (38, 39) . Injury upregulates Sur1 and activates the Sur1-Trpm4 complex, with cell depolarization from sodium influx, intracellular edema, and eventually cell death (29, 40) . There are advantages to studying this pathway in humans: 1) it is linked to edema in preclinical models including TBI, 2) it is not normally expressed in central nervous system (CNS) but upregulated by injury (29, 32) , 3) it is a potential preventative target for edema, and 4) it can be inhibited by glibenclamide (Food and Drug Administrationapproved for diabetes) at low, nonhypoglycemic doses (29) . Clinical trials (stroke and TBI) are evaluating the efficacy of glibenclamide. The recent phase-2 trial in stroke Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) was recently presented at the American Academy of Neurology and demonstrated extremely promising results with regards to cerebral edema. Although GAMES-RP was negative for its primary endpoint of dichotomized modified Rankin Scale score in the absence of decompressive hemicraniotomy, patients treated with glyburide (aka glibenclamide) had reduced mortality (14% vs 36%; p = 0.03) and decreased evidence of cerebral edema determined by midline shift between 72 and 96 hours (4.4 ± 3.6 vs 8.8 ± 4.9 mm; p = 0.0006) (41) . Sur1 upregulation has also been demonstrated in multiple cell types in human cerebral contusions (42) . However, to our knowledge, quantification of human Sur1 in cerebrospinal fluid (CSF) from patients with any CNS injury remains undefined.
Given the lack of serologic/CSF biomarkers for CE, preclinical evidence of Sur1 involvement in CE generation and the safety profile of an existing medication inhibiting this pathway, we undertook a bench-to-bedside pilot study to investigate Sur1 as a CSF biomarker, explore the relationship between CSF Sur1 in patients with severe TBI (sTBI) versus controls, and define associations between Sur1 and markers of CE or outcomes. We a priori hypothesized that Sur1 would be present in patients with sTBI, nondetectable in controls, and associated with CE.
MATERIALS AND METHODS

Study Design
Subjects were prospectively enrolled in the Brain-Trauma Research Center database. All patients had sTBI (Glasgow Coma Scale [GCS] score < 9 and placement of an external ventricular drain [EVD] per our standard care). Twenty-eight patients between 2011 and 2014 were randomly selected. Selection was blinded to outcomes. Control CSF was obtained from a biobank of 15 consecutively enrolled patients with normal pressure hydrocephalus (2008) (2009) . All subjects or healthcare proxies provided informed consent. The local institutional review board approved the study. CSF Sur1 quantification was performed using enzyme linked immunosorbent assay (Biosource) (Supplementary Fig. 3 , Supplemental Digital Content 7, http://links.lww.com/CCM/ C130; legend, Supplemental Digital Content 5, http://links.lww. com/CCM/C128). For TBI patients, mean and peak Sur1 values were also calculated. Assays were performed by a technician masked to demographic/outcome data. The mean coefficient of variation is less than 10%, and the minimum detectable Sur1 level is 0.118 ng/mL. TBI and control samples were paired on each plate to avoid interplate variability.
Data Collection
Demographic and outcome data were collected by an assistant masked to Sur1 levels. Five categories evaluated the association between Sur1, CE, and outcomes.
The presence of edema on initial head CT (determined by any of the following factors: compression of ventricles, effacement of basilar cisterns or sulci; transfalcine herniation; loss of gray/white matter differentiation) is associated with raised ICP after TBI (44, 45) and was included as an outcome. Determinations were made by two independent parties: 1) the official radiologist final report and 2) independent blinded trained investigator who reviewed each scan and evaluated CT edema on all patients. Any discrepancies between these two determinations were evaluated by a third blinded investigator, and adjudication was reached based on majority consensus. Hourly ICP measurements-subcategorized into means, peaks, continuous trend over time, initial ICP greater than 20 mm Hg, and number of measurements greater than 20 mm Hg during neuromonitoring. Therapies targeting edema: To account for practice variation, these included mannitol, hypertonic saline, hypothermia, neuromuscular blockade, or sedation. Decompressive craniotomy for refractory intracranial hypertension. Three-month Glasgow Outcome Scale (GOS): favorable (GOS ≥ 4) versus unfavorable outcome (GOS < 4).
Statistical Analysis
Descriptive statistics of baseline variables were reported as means ± se. Continuous variables were compared using Student t test, analysis of variance, or Wilcoxon rank-sum test as appropriate. Categorical variables were compared using Fisher exact tests. Kappa values determined inter-rater reliability for CT edema. Sur1 levels and ICP over time were graphed using connected plots. General ICP trends were determined using two-way median-spline curves-which were also used to estimate time-lags between peak Sur1 and peak ICP. Bivariate linear and logistic regression models were developed with clinically relevant variables in the evaluation of the independent relationship between Sur1 levels and outcomes. Exploratory multivariate logistic and linear regression models were developed with clinically relevant variables or those with a bivariate p value of less than 0.2 to control for confounders in evaluating the independent relationship between Sur1 and outcomes. No more than three variables were included in multiple regressions to avoid overfitting. Receiver operating characteristic (ROC) curves for these models were calculated. Tests were two tailed, and significance was determined by p values of less than 0.05. Post-hoc multiple comparisons were adjusted (Bonferroni's correction). Tests were performed using Stata 13.1(StataCorp, College Station, TX). Table 1 summarizes patient characteristics. There was a significant difference in age (p < 0.001) and sex with 22 of 28 TBI versus 1 of 15 control patients being men (p < 0.001). A total of 134 CSF samples were obtained from 28 patients at five timepoints (n = 119) and controls (n = 15).
RESULTS
Increased Sur1 After TBI Sur1 levels differed between sTBI patients and controls ( Fig. 1A ; p < 0.001). CSF Sur1 was undetectable in all controls. In sTBI, mean Sur1 was 3.53 ± 0.64 ng/mL and peak Sur1 was 7.13 ± 1.15 ng/mL. Sur1 levels were available in 119 of 140 potential CSF samples (28 patients × five time points = 140 potential CSF samples). Sur1 was detectable as early as 9 hours post injury and remained measurable over the first week, typically peaking at D2-3 (42.5 ± 6.24 hr), preceding edema development that mirrors this trajectory after a temporal delay ( Fig. 2A) .
Sur1 Is Associated With CT Edema
Inter-rater reliability was good (κ = 0.79), and there was nonagreement in only three cases, requiring the input of a third (blinded) research assistant. Mean Sur1 was higher in patients with edema on acute CT (4.96 ± 1.13 vs 2.10 ± 0.34 ng/mL; p = 0.023; Table 2 (Table 3) . Sur1 detection did not always precede ICP elevation. In nine cases, the first ICP measurement greater than 20 mm Hg occurred before Sur1 detection suggesting that non-Sur1-related CE pathways likely predominated acutely. These ICP elevations were not peak measurements. Based on preclinical models, we hypothesized that peak Sur1 levels would precede maximum CE (reflected by peak ICP). We aimed to determine the temporal delay between these two events because this might aid in stratifying high-risk patients and therapy timing.
Sur1 peaked by 42.5 ± 6.24 hours and was mostly followed by peak ICP after a variable time interval. The correlation between time-to-peak Sur1 and ensuing time-to-peak ICP in all patients approached significance (Pearson ρ = 0.33 weak; β-coefficient = 0.61; p = 0.089). Four patients had no ICPs greater than 20 mm Hg. In 22 of the remaining patients (91.7%), peak Sur1 preceded peak ICP. The delay for ensuing peak ICP from time of peak sur1 was 82.5 ± 11.75 hours.
Examination of temporal Sur1 and ICP trends provided a more granular characterization and confirmed the aforementioned aggregate pattern where peak Sur1 was followed by peak ICP after a variable delay. Four categories of time-intervals between Sur1 and ICP peaks emerged that differed from one another (corrected p < 0.005 for all groups; Supplementary  Fig. 1 , Supplemental Digital Content 2, http://links.lww. com/CCM/C125; legend, Supplemental Digital Content 5, http://links.lww.com/CCM/C128; and Supplementary Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/CCM/ C126; legend, Supplemental Digital Content 5, http://links. lww.com/CCM/C128). In many patients (Fig. 2B) , ICP trajectory and not just peak reflected the Sur1 pattern after a variable temporal interval.
Sur1 Trajectories Were Associated With ICP Elevation and Outcomes. There was no association between mean/ peak Sur1with mean/peak ICP, proportion of ICP measurements greater than 20 mm Hg (Table 3) , use of edema-directed therapies, decompressive craniotomy, or 3-month GOS. Given the clinical variability of TBI, CE, and potential individual patient point values of Sur1 and sensitivities to this pathway, we hypothesized that Sur1 trajectory might better define intracranial hypertension development/resolution and outcomes (Supplementary Table 2 , Supplemental Digital Content 4, http://links.lww.com/CCM/C127). Sur1 trajectories between 48 and 72 hours revealed significant associations between GOS and edema ( Fig. 2C and Table 4 ). Precipitous declines in Sur1 were associated with favorable outcomes (3-mo GOS ≥ 4; p = 0.0268). Patients with sTBI who had no episodes of intracranial hypertension during their ICU course had different Sur1 trajectories between 48 and 72 hours versus patients with ICP spikes(p = 0.0456). Sur1 in patients without intracranial hypertension declined during this time period (-4.82 ± 3.54 ng/mL) versus the latter group where levels rose or decreased minimally (0.10 ± 0.80 ng/mL). Similarly, patients with less than 3 ICP spikes had declining Sur1 between 48 and 72 hours (-3.56 ± 2.62) versus those with multiple ICP measurements greater than 20 mm Hg (0.41 ± 0.68; p = 0.048). This trend was also noted in Sur1 level between 12 and 24 hours; however, it was not statistically significant (Supplementary  Table 2 , Supplemental Digital Content 4, http://links.lww.com/ CCM/C127).
Thus, rises or minimal changes in Sur1 between 48 and 72 hours were associated with ICP elevations and unfavorable outcomes, while declining Sur1 during this time period correlated with negligible/no intracranial hypertension and favorable outcomes. Area under ROC curves generated from Initial Glasgow Coma Scale, mean ± se 6 ± 2 NA regression models of Sur1 trajectory, initial GCS score, and CT edema was 0.881 for dichotomized GOS (Fig. 2D) .
DISCUSSION
There have been many failed clinical TBI trials largely attributed to disease heterogeneity and lack of informative biomarkers (46, 47) . CE is a common cause of in-hospital death in sTBI. A biomarker predicting its development might identify patients at-risk, evaluate disease progression, develop, target and monitor treatment, and guide prognostication. Surprisingly, there are no clinically available CSF or circulating biomarkers for CE in TBI (akin to troponin levels). This could reflect recognition of challenges related to clinical variability of TBI pathology and the multiple molecular pathways involved. However, in truth, markers of CE have simply not been the focus of TBI biomarker development. Notwithstanding the challenges, the existence of different underlying mechanisms fundamental to edema generation presents an opportunity to develop biomarkers to categorize patients and guide individualized, molecularly precise therapies. Such biomarkers could prove invaluable to management. Although ICP monitoring has been a cornerstone, it alone is insufficient to guide therapy (12) . ICP measurements in isolation do not reflect differences in the subtypes of edema that may require different approaches (12) . Supportive data from imaging, neurological examinations, and biomarkers are valuable adjuncts. Sur1 is a promising and novel target: it has a pathophysiologic basis, its role in a specific pathway of CE is established in animal models (29-31), Sur1-Trpm4 upregulation is specific to CNS injury and is seen in human contusions (29, 32, 42) , and inhibition of this receptor by glibenclamide in animal models and early clinical trials in ischemic stroke has reduced the development of edema and improved outcomes (29) (30) (31) 41 ). This study is exploratory and hypothesis generating. It has four central findings that strengthen the hypothesis of Sur1 as a useful biomarker in TBI to predict/monitor CE: 1) Sur1 was present in TBI but undetectable in controlsthis finding links prior preclinical work and pathophysiology to human studies, 2) mean and peak Sur1 levels were correlated with signs of edema on acute CT, 3) there was a temporal delay between peak Sur1 and peak ICP, and 4) declining Sur1 at 48-72 hours was associated with less odds of intracranial hypertension and greater odds of favorable outcomes. Our data may also inform on preventative therapeutic windows and identify patients at-risk for edema Figure 1 . A, Sulfonylurea receptor 1 (Sur1) levels differed between patients with severe traumatic brain injury (sTBI) versus controls (p < 0.001). The plot depicts the median (2.89 ng/mL) and interquartile range (1.32-3.97 ng/mL) of Sur1 in sTBI compared with the undetectable levels in controls. B, The difference in both mean (p = 0.023) and peak (C, p = 0.019) Sur1 levels between patients with and without edema on acute CT was statistically significant with higher levels noted in patients who had evidence of edema on acute CT. A higher presenting Glasgow Coma Scale score tended to decrease the odds of edema on acute CT (odds ratio, 0.59; 95% CI, 0.34-1.00; p = 0.055, not shown).
development. However, this is tempered by a lack of association between mean/peak Sur1 and mean/peak ICP, proportion of ICP greater than 20 mm Hg, use of edema-directed therapies, decompressive craniotomy or 3-month Glasgow Outcome Scale. This may reflect the limited sample size/ power, patient-specific differences in degrees of receptor expression/sensitivity, and/or genetic variability (48, 49) . It is also possible that, particularly given the complexity of cerebral edema in TBI, mean/peak Sur1 levels over 5 days do not provide the adequate granularity with which to evaluate associations with cerebral edema or outcomes-many other biomarkers (such as troponins or creatinine levels) are followed at more frequent temporal intervals. Other limitations include varying treatment strategies/intensities. Given the multiple pathways implicated in edema generation, in some patients, alternative mechanisms may supersede and/ or complement Sur1.
Sur1 and Radiographic Edema
Edema on acute CT was associated with the degree of initial ICP elevation. However, the continued use of serial surveillance CTs is less practical than a CSF biomarker for reasons including radiation exposure, transport-related complications, and artifact. Furthermore, CT is neither quantitative nor useful for predicting development or timing of intracranial hypertension but rather is obtained in response to elevated ICPs or clinical deteriorations. A biomarker to reduce CT scan frequency and assist with early identification, monitoring, and treatment of TBI patients likely to develop CE could improve care. We sought to determine whether there was a correlation between Sur1 and CT edema to lay the foundation for future studies to evaluate whether monitoring Sur1 could represent an adjunctive index.
We observed an association between Sur1 and CE on acute CT. Thus, the Sur1 pathway may provide one pathophysiologic explanation for subsequent raised ICP in some patients. If ) had large declines in Sur1 (red, -3.73 ± 2.33 ng/mL) versus those with poor outcomes who had slight increases in Sur1 (blue, 0.48 ± 0.61) (p = 0.0268). Declining Sur1 levels during this time period were also associated with patients without any ICP spikes or less than 3 ICP spikes (red, -4.82 ± 3.54 and -3.56 ± 2.62 ng/mL, respectively) versus those who had intracranial hypertension and Sur1 either increased slightly or minimally declined (blue, 0.10 ± 0.80, p = 0.0456 and 0.41 ± 0.68, p = 0.048, respectively). Area under receiver operating characteristic (ROC) curves for models containing 48-72 hr Sur1 trajectory, initial Glasgow Coma Scale and edema on acute CT was 0.881 for GOS (D).
validated in larger studies, Sur1 could represent a therapeutic target in a subgroup of patients with sTBI. Our exploratory data provide groundwork for future research addressing issues such as patient stratification and prognostication, phenotyping for evaluation of efficacy of agents targeting the Sur1 pathway, and/or utility of CSF Sur1 as an adjunct in decision making for current therapies targeting brain edema.
Sur1, Clinical Edema, and Outcomes
Mean and peak Sur1 levels were associated with the magnitude of the initial episode of intracranial hypertension. This measure of ICP is the least contaminated by treatments. Mean/ peak Sur1 levels were not associated with multiple other measures of edema or outcomes as discussed above.
Sur1 Timing, Clinical Edema, and Outcomes
Multiple molecular pathways likely regulate the development of CE. Nine patients had intracranial hypertension before Sur1 detection. This could reflect pericontusional edema from vasogenic swelling, mass effect, and/or increased tissue osmolality (8, 9) . Conversely, cellular edema can begin as early as 40-60 minutes post injury and continue for 7-14 days (7, 8) . The time taken for Sur1 to peak preceded peak ICP measurements in 91.7% of patients, supporting the theory that this pathway may mediate edema development. Early increases in CSF Sur1 may portend intracranial hypertension to follow over the subsequent 24-100 hours. As ICP increases, Sur1 levels decrease-possibly due to an evolutionary protective feedback mechanism although additional study is needed to address this possibility. 
LIMITATIONS
Our study is single-center and associative. Although our results are supported by preclinical data, the relationship of Sur1 to CE may be an epiphenomenon. The mechanism by which Sur1 becomes detectable in CSF remains unclear, as is its sourcealthough not the focus of this article, this warrants exploration. Sur1 levels at injury were not obtainable, and 12-hour Sur1 was unavailable in 10 patients. The use of ICP as a proxy for CE is imperfect. Furthermore, hourly ICP measurements do not account for simultaneous exposures to other treatments Notwithstanding an existing ICP treatment protocol, practitioner preferences could introduce misclassification bias. The use of a validated measure such as "therapeutic intensity level" (51) was unavailable and warrants investigation in larger studies. Nonetheless, declining Sur1 trajectory between 48 and 72 hours was significantly associated with no intracranial hypertension regardless of the underlying etiology (therapeutic maneuvers or spontaneous resolution), suggesting the potential value of Sur1 in ICP resolution in response to either therapeutic maneuvers or spontaneous improvement.
There was an age and sex difference between patients and controls, potentially confounding the results; however, control samples from a cohort of eight pediatric patients (50% male, unpublished) also had undetectable Sur1. Given this absence of Sur1 in control CSF, it is highly unlikely that the observed differences in Sur1 between TBI and controls were related to age or sex differences.
CONCLUSIONS
Burgeoning medical technologies and genetic/molecular markers are increasingly allowing for targeted/individualized therapies in many fields. No such markers are available to evaluate CE in sTBI. Given the pathophysiologic pathway elucidated by preclinical models and its potential as a therapeutic focus, Sur1 is an appealing target to begin complementing traditional measures of edema like ICP and CT with molecular biomarkers. To our knowledge, this is the first report quantifying human CSF Sur1. Levels were detected in all patients with sTBI but undetectable in all controls and mean and peak Sur1 levels correlated with edema on CT. We showed a relationship between timing of Sur1 upregulation and development of peak ICP. Although there was no association between absolute values of mean/peak Sur1 with several measures of cerebral edema, declining Sur1 trajectory particularly between 48 and 72 hours may anticipate edema resolution. Monitoring Sur1 trajectory may therefore be a useful, patient-specific, adjunct to ICP and inform timing of therapy and need for additional resource intensity. It is also possible that Sur1 levels may provide information about patients who are more or less likely to respond to a therapy inhibiting this pathway. Because an existing inhibitor of Sur1 (Glibenclamide) is being evaluated in clinical trials and appears to potentially prevent brain edema in susceptible patients, larger studies validating our preliminary findings of the relationships between Sur1, CE and outcomes are warranted.
